Birzeit Pharmaceutical Co (XPAE:BPC) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Birzeit Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Birzeit Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Birzeit Pharmaceutical Co's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Birzeit Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Birzeit Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Birzeit Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Birzeit Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

Birzeit Pharmaceutical Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Birzeit Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Birzeit Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0	/	128.821
	=	0.00

Birzeit Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0	/	128.821
	=	0.00

Birzeit Pharmaceutical Co (XPAE:BPC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Birzeit Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Birzeit Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Birzeit Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Birzeit Pharmaceutical Co (XPAE:BPC) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Industrial Zone, P.O. Box 79, Ramallah, PSE

Website

https://www.bpc.ps

Birzeit Pharmaceutical Co is engaged in manufacturing pharmaceutical products. It produces Ampoules, Capsules, Tablets and Caplets, Syrups, Suspensions and Granules, Ophthalmic, Semi-solids, Powder vials, Suppositories, and Powders. It serves the Ministry of Health, local healthcare organizations, international healthcare organizations and programs, and end users through pharmacies and physicians. It carries out its activity in Palestine, Algeria, and East Europe.

Birzeit Pharmaceutical Co Headlines

No Headlines